Intercept Pharmaceuticals (NASDAQ:ICPT) has submitted a marketing application to the FDA seeking approval of obeticholic acid for the treatment of patients with fibrosis due to nonalcoholic steatohepatitis (NASH).
It plans to file an application in Europe in Q4.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.